Local acting Sticky‐trap inhibits vascular endothelial growth factor dependent pathological angiogenesis in the eye. Issue 5 (4th April 2014) - Michael, Iacovos P
Synopsis A locally delivered, bifunctional recombinant "Sticky‐trap" comprising a VEGF‐trap and a heparin‐binding domain (HBD) can prevent aberrant ocular angiogenesis without affecting systemic physiological VEGF‐processes. Bifunctional "Sticky‐trap" is comprised of VEGF‐trap and a carboxy‐terminal HBD. Treatment with recombinant Sticky‐trap can prevent the development of abnormal ocular angiogenesis. Sticky‐trap remains at the site of delivery; thus, it has a local antiangiogenic activity. Sticky‐trap applied in the eye does not compromise systemic physiological VEGF‐processes, such as wound healing and kidney function.